The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The requested identity is verified: human CCND1 at chromosome 11q13.3 encodes cyclin D1, also historically called BCL-1/BCL1 and PRAD1. It is a member of the D-type cyclin family, not a similarly named gene from another organism. The canonical protein is a 295-amino-acid, non-catalytic regulatory protein containing the expected cyclin-fold domains and regulatory C terminus. The literature therefore aligns with the supplied UniProt accession P24385 and domain annotations; no ambiguous-symbol literature was used. (saleban2023dtypecyclinsin pages 3-4, saleban2023dtypecyclinsin pages 8-10, saleban2023dtypecyclinsin pages 1-3, tchakarska2020thedoubledealing pages 26-30)
Its primary function is to convert extracellular mitogenic signals into cell-cycle commitment. Cyclin D1 binds CDK4 or CDK6 and activates the kinase complex; cyclin D1 itself does not catalyze a chemical reaction. Nuclear cyclin-D1–CDK4/6 phosphorylates RB-family pocket proteins, diminishes RB-mediated repression of E2F transcription factors, and permits expression of genes required for G1-to-S progression. Thus, the relevant substrate specificity belongs to the assembled serine/threonine-kinase holoenzyme, with RB1/RBL-family proteins among its best-established physiological substrates. (taha2024ccnd1asa pages 2-3, tchakarska2020thedoubledealing pages 26-30, tchakarska2020thedoubledealing pages 5-9, tchakarska2020thedoubledealing pages 17-21)
| Category | Evidence-based annotation | Key evidence or quantitative detail | Interpretation and strength |
|---|---|---|---|
| Verified identity | UniProt P24385 is human CCND1, encoding cyclin D1; aliases include BCL1/BCL-1 and PRAD1. The canonical protein is 295 aa, belongs to the D-type cyclin family, and is distinct from CCND2 and CCND3. | CCND1 maps to 11q13.3; literature independently matches the human cyclin D1, BCL-1, and PRAD1 identity (saleban2023dtypecyclinsin pages 8-10, saleban2023dtypecyclinsin pages 1-3, tchakarska2020thedoubledealing pages 26-30). | High confidence: curated accession details supplied in the query agree with the literature; no conflicting same-symbol protein was identified. |
| Domains and regulatory features | Cyclin D1 contains conserved Cyclin_N/C cyclin-box architecture for CDK4/6 binding, an RB-binding LxCxE motif, a C-terminal PEST region/Thr286 phosphodegron, and an LxxLL motif supporting nuclear-receptor interactions. | The cyclin box spans approximately 100 aa. Alternative cyclin D1b retains the cyclin box but has a distinct C terminus and lacks canonical turnover and regulatory features (saleban2023dtypecyclinsin pages 3-4, tchakarska2020thedoubledealing pages 26-30, tchakarska2020thedoubledealing pages 33-34). | High confidence for cyclin-box architecture and Thr286 regulation; isoform-specific activities are more context dependent. |
| Primary molecular function | Cyclin D1 is a non-catalytic regulatory subunit, not an enzyme. It binds and activates CDK4 and CDK6; the resulting kinase complex phosphorylates RB-family proteins, weakens RB-mediated E2F repression, and enables transcription required for the G1-to-S transition. | Biochemical, genetic, and inhibitor evidence consistently places cyclin D1 upstream of RB phosphorylation and E2F activation (taha2024ccnd1asa pages 2-3, tchakarska2020thedoubledealing pages 26-30, tchakarska2020thedoubledealing pages 5-9, tchakarska2020thedoubledealing pages 17-21). | Established canonical function: catalysis is performed by CDK4/6, with RB1 and related pocket proteins serving as prominent holoenzyme substrates. |
| Localization and turnover | Its canonical cell-cycle function occurs mainly in the nucleus during G1. Cyclin D1 lacks a conventional nuclear-localization signal; CDK4/6 and NLS-bearing p21/p27 facilitate assembly and import. At S-phase entry, Thr286 phosphorylation promotes XPO1-dependent export, ubiquitination, and proteasomal degradation. | Localization studies summarized in 2023 reported nuclear complexes in 76% ± 9.6% of cells with p21 versus 5.2% ± 3.0% without exogenous p21. Loss of Thr286-dependent turnover causes stabilization and nuclear retention (radel2023investigatingposttranslationalmodification pages 20-23, tchakarska2020thedoubledealing pages 5-9, tchakarska2020thedoubledealing pages 1-5). | Strong mechanistic evidence: the relevant kinases and E3 ligases can vary by context, but the phosphorylation-export-degradation framework is robust. |
| Upstream signaling | CCND1 acts as a mitogen sensor downstream of receptor-tyrosine-kinase signaling. RAS-RAF-MEK-ERK promotes transcription, whereas PI3K-AKT supports translation, complex assembly, and stability; WNT/β-catenin and NF-κB contribute in selected contexts. | Mitogen-dependent induction and p21/p27-assisted complex assembly couple extracellular growth signals to CDK4/6-RB-E2F activation (saleban2023dtypecyclinsin pages 3-4, radel2023investigatingposttranslationalmodification pages 20-23, tchakarska2020thedoubledealing pages 1-5). | High confidence for RAS/MAPK and PI3K/AKT inputs; relative pathway importance varies by tissue and disease. |
| Noncanonical functions | Cyclin D1 can act as a transcriptional coregulator with nuclear receptors and chromatin modifiers, participate in BRCA2-RAD51-associated homologous recombination, and regulate cytoskeletal organization, migration, invasion, and metabolism. Some functions are CDK4/6 independent. | Reducing cyclin D1, but not merely inhibiting CDK4/6, decreased RAD51 recruitment after DNA damage. Cytoplasmic cyclin D1 affects ROCK, TSP1, and RAC1-associated motility pathways (tchakarska2020thedoubledealing pages 13-17, saleban2023dtypecyclinsin pages 4-6, saleban2023dtypecyclinsin pages 3-4). | Moderate-to-strong experimental evidence, but these activities are context specific and do not displace the CDK4/6-RB axis as the primary annotation. |
| 2023 neuronal finding | In post-mitotic neurons, cytoplasmic cyclin D1-CDK4 directly binds the intracellular loop of GABAA-receptor α4/GABRA4 and phosphorylates T423 and S431, increasing receptor surface abundance and inhibitory signaling. | Palbociclib or non-phosphorylatable α4 reduced tonic currents and miniature-IPSC amplitude and frequency in newborn-rat hippocampal preparations. CCND1-knockout mouse neurons had increased mushroom-spine density, rescued by phosphomimetic α4. Published 8 September 2023; DOI 10.1007/s00018-023-04920-7 (pedraza2023cyclind1—cdk4regulates pages 10-13, pedraza2023cyclind1—cdk4regulates pages 1-2, pedraza2023cyclind1·cdk4regulates pages 10-13). | Strong direct evidence from binding, site-specific mutants, electrophysiology, knockout, and rescue experiments; relevance to adult human physiology remains unestablished. |
| Mantle-cell lymphoma application | t(11;14)(q13;q32)/IGH::CCND1 drives constitutive cyclin D1 expression in virtually all conventional mantle-cell lymphomas. Cyclin D1 immunohistochemistry and CCND1 FISH are important diagnostic tools when integrated with morphology, CD5, SOX11, and other findings. | Rare IGK::CCND1 and IGL::CCND1 variants occur. A 2024 expert review emphasizes that CCND1 alteration is characteristic but not absolutely exclusive to MCL (lopez2024biologicalandclinical pages 1-2). | Established clinical diagnostic application, but neither cyclin D1 positivity nor a CCND1 rearrangement should be interpreted in isolation. |
| 2024 lymphoma caveat | CCND1 rearrangement can occur in aggressive large B-cell lymphomas through mechanisms distinct from canonical MCL. In a 13-case SOX11-negative cohort, 3/13 rearrangements were V(D)J mediated, 10/13 arose through class-switch recombination or somatic hypermutation, and 6 carried BCL6 rearrangements. | Cyclin D1 is expressed in approximately 1-2% of DLBCL, usually without CCND1 translocation. Published September 2024; DOI 10.1038/s41408-024-01146-z (ozogul2024largebcelllymphomas pages 1-2, ozogul2024largebcelllymphomas pages 5-7). | Strong diagnostic caution from a small molecular cohort: breakpoint mechanism, SOX11/CD5, morphology, and genomic context help distinguish MCL from CCND1-rearranged large B-cell lymphoma. |
| 2024 pan-cancer statistics | Database analysis across 33 cancer types found significant CCND1 elevation in 13 and identified amplification as the predominant alteration; the direction of expression-prognosis associations differed among cancers. | Across 46,206 patients, 2,385 CCND1-altered cases had median overall survival of 39.66 months, versus 46.92 months in 43,821 unaltered cases; p=5.98×10⁻³ and q=0.0239. Disease-specific, disease-free, and progression-free survival differences were nonsignificant. Published 27 July 2024; DOI 10.7759/cureus.65504 (taha2024ccnd1asa pages 22-26, taha2024ccnd1asa pages 1-2). | Hypothesis-generating rather than clinical-grade: this was a large but retrospective and heterogeneous public-data analysis without prospective or wet-laboratory validation. |
| Clinical targeting and resistance | CCND1 itself is not routinely drugged; treatment inhibits its catalytic partners. Palbociclib, ribociclib, and abemaciclib plus endocrine therapy implement cyclin-D-CDK4/6-RB pathway inhibition in HR-positive/HER2-negative breast cancer. Benefit generally requires functional RB. | Reported median PFS values were PALOMA-2 27.6 versus 14.5 months, MONARCH-3 28.2 versus 14.8, MONALEESA-2 25.3 versus 16.0, and MONALEESA-3 20.5 versus 12.8. Resistance mechanisms include RB loss, cyclin-E/CDK2 activation or CCNE1 amplification, and PI3K-AKT-mTOR or ER-pathway adaptation (tchakarska2020thedoubledealing pages 17-21, zhao2023anarrativereview pages 13-15, zhao2023anarrativereview pages 1-2). | Established therapeutic validation of the pathway, but not proof that CCND1 amplification alone predicts response. Resistance is multifactorial, and continuation beyond progression is not routinely standard without an appropriate clinical or biomarker context. |
Table: Concise evidence matrix for verified human cyclin D1 identity, molecular function, localization, recent mechanistic findings, diagnostic use, quantitative cancer data, and therapeutic relevance.
CCND1 is one of three mammalian D-type cyclin genes, alongside CCND2 and CCND3. The proteins share approximately 57% coding-sequence identity but have distinct chromosomal positions and partially tissue-specific requirements; CCND1 is located at 11q13.3 and is broadly expressed. This distinguishes P24385 from the cyclin-D2 and cyclin-D3 proteins despite their related functions. (saleban2023dtypecyclinsin pages 3-4, saleban2023dtypecyclinsin pages 1-3)
The canonical cyclin D1 protein contains conserved Cyclin_N and Cyclin_C/cyclin-box architecture, which creates the interaction surface for CDK4/6. Reported functional features include an RB-binding LxCxE motif, an approximately 100-residue conserved cyclin box, a C-terminal PEST region, the Thr286 phosphodegron, and an LxxLL motif that contributes to nuclear-receptor interactions. Alternative splicing produces cyclin D1b, whose altered C terminus removes important localization and degradation controls; consequently, results obtained for D1b should not automatically be assigned to canonical P24385 cyclin D1a. (saleban2023dtypecyclinsin pages 3-4, tchakarska2020thedoubledealing pages 26-30, tchakarska2020thedoubledealing pages 33-34)
Cyclin D1 is best described as a mitogen-responsive kinase-regulatory subunit. Receptor-tyrosine-kinase signaling through RAS–RAF–MEK–ERK induces CCND1 transcription, while PI3K–AKT signaling supports translation, assembly, stability, and nuclear accumulation. WNT/β-catenin and NF-κB can also induce CCND1 in particular tissues or disease states. This position makes cyclin D1 a molecular integrator rather than a constitutively active cell-cycle enzyme. (saleban2023dtypecyclinsin pages 3-4, radel2023investigatingposttranslationalmodification pages 20-23, tchakarska2020thedoubledealing pages 1-5)
Cyclin D1 binds CDK4 or CDK6 through its cyclin box and induces the kinase conformation needed for substrate phosphorylation. The CIP/KIP proteins p21 and p27 have a dual role: although they inhibit some other CDKs, they can promote assembly and nuclear import of cyclin-D–CDK4/6 complexes. Activated complexes phosphorylate RB1 and related pocket proteins, weakening RB–E2F association and enabling E2F-dependent transcription. Subsequent cyclin-E–CDK2 activity reinforces RB inactivation and S-phase entry. (tchakarska2020thedoubledealing pages 26-30, radel2023investigatingposttranslationalmodification pages 20-23, tchakarska2020thedoubledealing pages 5-9)
This model should be stated precisely: cyclin D1 has no intrinsic kinase activity, and RB is phosphorylated by CDK4/6 within the complex. Moreover, cyclin-D–CDK4/6 activity is important but not universally sufficient for proliferation; RB status, cyclin E/CDK2 activity, CDK inhibitors, and mitogenic context determine the cellular response. (tchakarska2020thedoubledealing pages 1-5, tchakarska2020thedoubledealing pages 17-21)
Ccnd1-deficient mice have reduced body size, retinal hypoplasia, defective pregnancy-induced mammary development, and increased early mortality. Rescue of retinal and mammary abnormalities by a kinase-defective Ccnd1 K112E allele indicates that some developmental functions do not require conventional CDK4/6 catalysis. These findings support both the canonical kinase-regulatory role and genuine CDK-independent functions. (saleban2023dtypecyclinsin pages 3-4)
The canonical cell-cycle function occurs principally in the nucleus during G1. Cyclin D1 lacks a conventional autonomous nuclear-localization signal; association with CDK4/6 and NLS-containing p21 or p27 facilitates import. Localization studies summarized in 2023 reported intense nuclear cyclin-D1–CDK4 staining in 76% ± 9.6% of cells expressing p21, compared with 5.2% ± 3.0% without exogenous p21, illustrating the importance of complex assembly for trafficking. (radel2023investigatingposttranslationalmodification pages 20-23)
At the G1/S boundary, phosphorylation of canonical cyclin D1 at Thr286 promotes recognition by the XPO1/CRM1 nuclear-export machinery. Cytoplasmic cyclin D1 is then polyubiquitylated and degraded by the proteasome. CRL4–AMBRA1 and several context-dependent SCF-associated ligases have been implicated in turnover. Mutation or deletion of Thr286, loss of the C-terminal PEST region, cyclin D1b splicing, altered 3′ UTRs, or deubiquitylation can stabilize cyclin D1 and produce inappropriate nuclear persistence. (saleban2023dtypecyclinsin pages 3-4, tchakarska2020thedoubledealing pages 5-9, tchakarska2020thedoubledealing pages 1-5)
Cyclin D1 can also occur in the cytosol, at membrane-associated structures, and near mitochondria. These pools have reported roles in cytoskeletal dynamics, migration, invasion, receptor trafficking, and metabolism. Localization is therefore functional rather than incidental: nuclear accumulation generally favors cell-cycle and transcriptional effects, whereas cytoplasmic cyclin D1 can regulate motility or differentiated-cell signaling. (tchakarska2020thedoubledealing pages 1-5, tchakarska2020thedoubledealing pages 13-17)
Cyclin D1 interacts with estrogen and androgen receptors, other transcription factors, coactivators, histone acetyltransferases, deacetylases, and chromatin regulators. These interactions can alter transcription independently of RB phosphorylation and, in some settings, independently of CDK4/6. Its LxxLL motif is relevant to nuclear-receptor regulation. (saleban2023dtypecyclinsin pages 3-4, tchakarska2020thedoubledealing pages 33-34)
After DNA damage, cyclin D1 can associate with BRCA2–RAD51 machinery and accumulate at γH2AX-marked damage sites. Reduced cyclin D1 expression decreases RAD51 recruitment, whereas CDK4/6 inhibition alone does not reproduce the effect, supporting a CDK-independent contribution to homologous recombination. Cyclin D1 has also been connected to DNA-PK and non-homologous end joining, although these repair activities are less universal than the RB pathway. (tchakarska2020thedoubledealing pages 13-17, saleban2023dtypecyclinsin pages 4-6)
In motility and invasion, cytoplasmic cyclin D1 can inhibit ROCK signaling, reduce thrombospondin-1, interact with paxillin, activate RAC1-associated membrane ruffling, and remodel the cytoskeleton. It also affects glycolytic, lipogenic, and mitochondrial programs through proteins such as HK2, VDAC, PGC1α, ChREBP, HNF4α, and NRF1. These are supported by biochemical and model-system evidence but remain strongly cell-type dependent; they should be treated as secondary functional annotations rather than replacing the canonical CDK4/6–RB role. (tchakarska2020thedoubledealing pages 13-17, saleban2023dtypecyclinsin pages 4-6)
A particularly precise 2023 study identified a function for cytoplasmic cyclin-D1–CDK4 in post-mitotic neurons. Cyclin D1 directly bound the intracellular loop of the GABA-A receptor α4 subunit, GABRA4, and the associated kinase phosphorylated α4 at Thr423 and Ser431. These modifications increased α4 surface abundance and enhanced α4-containing receptor activity. Pedraza et al., published online 8 September 2023, DOI 10.1007/s00018-023-04920-7. (pedraza2023cyclind1—cdk4regulates pages 10-13, pedraza2023cyclind1·cdk4regulates pages 1-2, pedraza2023cyclind1—cdk4regulates pages 1-2)
The conclusion was supported by complementary experiments: palbociclib or non-phosphorylatable α4 reduced extrasynaptic tonic currents and miniature inhibitory-postsynaptic-current amplitude and frequency in newborn-rat hippocampal preparations; phosphomimetic α4 produced opposite effects. CCND1-knockout mouse neurons had increased mature mushroom-spine density, and phosphomimetic α4 rescued the phenotype. Binding, mapped phosphosites, electrophysiology, knockout, and rescue collectively provide strong mechanistic evidence. Its quantitative importance in adult human neurons, however, is not yet established. (pedraza2023cyclind1—cdk4regulates pages 10-13, pedraza2023cyclind1·cdk4regulates pages 13-16, pedraza2023cyclind1·cdk4regulates pages 10-13)
CCND1 becomes oncogenic through amplification, enhancer or immunoglobulin-locus rearrangement, excessive mitogenic transcription, increased mRNA stability, impaired Thr286-dependent degradation, or abnormal nuclear retention. Persistent activity shortens G1, compromises replication checkpoints, and can promote replication stress, DNA damage, aneuploidy, and genomic instability. Overexpression alone is not always transforming; cooperating lesions and the cellular lineage determine whether it drives malignancy. (saleban2023dtypecyclinsin pages 3-4, tchakarska2020thedoubledealing pages 17-21, saleban2023dtypecyclinsin pages 4-6)
Cyclin D1 overexpression has been reported in more than half of breast cancers, but expression and amplification are not equivalent, and neither is by itself a universally validated response biomarker. In animal models, cyclin D1 loss or kinase-defective cyclin D1 protects against ErbB2/Ras-driven mammary tumors, whereas degradation-resistant nuclear cyclin D1 promotes lymphoma and accelerates mammary carcinogenesis. (tchakarska2020thedoubledealing pages 13-17, tchakarska2020thedoubledealing pages 17-21, saleban2023dtypecyclinsin pages 3-4)
The archetypal clinical implementation of CCND1 testing is mantle-cell lymphoma. Conventional MCL is characteristically associated with t(11;14)(q13;q32)/IGH::CCND1, which places CCND1 under immunoglobulin regulatory control and causes constitutive cyclin D1 expression. Rare IGK::CCND1 and IGL::CCND1 variants also occur. Cyclin D1 immunohistochemistry and CCND1 FISH are therefore important diagnostic tests, interpreted together with morphology, CD5, SOX11, and the broader immunophenotype. López et al., Blood Advances, 23 July 2024, DOI 10.1182/bloodadvances.2023011763. (lopez2024biologicalandclinical pages 1-2)
An important 2024 refinement is that cyclin D1 positivity or CCND1 rearrangement is not absolutely specific for MCL. Özoğul et al. studied 13 SOX11-negative aggressive B-cell lymphomas with CCND1 rearrangement. Only 3/13 had V(D)J-mediated events; 10/13 arose through class-switch recombination or somatic-hypermutation mechanisms, and six carried BCL6 rearrangements. These latter tumors were principally large B-cell lymphomas with DLBCL-like genomic profiles. Cyclin D1 expression occurs in approximately 1–2% of DLBCL, often without a CCND1 translocation. Published September 2024, DOI 10.1038/s41408-024-01146-z. (ozogul2024largebcelllymphomas pages 1-2, ozogul2024largebcelllymphomas pages 5-7)
The expert diagnostic implication is clear: do not diagnose MCL from cyclin D1 immunoreactivity or CCND1 break-apart FISH alone. Large-cell morphology, SOX11/CD5 negativity, BCL6 or MYC-associated lesions, class-switch-region breakpoints, and a DLBCL-like mutation profile support a large B-cell lymphoma instead. The 2024 cohort is small, but its breakpoint and genomic data make the biological distinction persuasive. (ozogul2024largebcelllymphomas pages 1-2, lopez2024biologicalandclinical pages 1-2)
CCND1 itself is not routinely inhibited directly. Clinical therapy instead targets its catalytic partners with CDK4/6 inhibitors. Palbociclib, ribociclib, and abemaciclib combined with endocrine therapy have established the cyclin-D–CDK4/6–RB pathway as a therapeutically actionable dependency in hormone-receptor-positive/HER2-negative breast cancer. Open Targets likewise records approved-stage clinical evidence connecting CCND1-associated pathway targeting with breast cancer. (OpenTargets Search: -CCND1, zhao2023anarrativereview pages 1-2)
Representative first-line advanced-disease trial results summarized in a 2023 clinical review include median progression-free survival of 27.6 versus 14.5 months for palbociclib plus letrozole versus letrozole in PALOMA-2; 28.2 versus 14.8 months for abemaciclib plus a nonsteroidal aromatase inhibitor in MONARCH-3; 25.3 versus 16.0 months for ribociclib plus letrozole in MONALEESA-2; and 20.5 versus 12.8 months for ribociclib plus fulvestrant in MONALEESA-3. Zhao et al., June 2023, DOI 10.21037/tcr-22-2807. (zhao2023anarrativereview pages 1-2)
These therapies validate the pathway, not CCND1 amplification as a stand-alone companion diagnostic. Functional RB is generally needed for durable cytostatic activity. Resistance can emerge through RB loss, cyclin-E/CDK2 activation, CCNE1 amplification, altered p21/p27, PI3K–AKT–mTOR signaling, persistent ER signaling, and microenvironmental adaptation. Expert reviews therefore favor molecular reassessment after progression and rational combinations rather than assuming that high cyclin D1 guarantees continued CDK4/6 dependence. (tchakarska2020thedoubledealing pages 17-21, zhao2023anarrativereview pages 13-15)
The evidence for continuing CDK4/6 inhibition after radiographic progression is heterogeneous. Switching inhibitor or endocrine partner has produced modest benefit in selected studies, but biomarker-unselected continuation of the same agent is not a general standard. After progression, actionable alterations in PIK3CA, ESR1, AKT/PTEN, and germline BRCA1/2 or PALB2 can guide endocrine-targeted combinations, AKT/PI3K/mTOR inhibitors, or PARP inhibitors. (zhao2023anarrativereview pages 13-15, giachetti2025survivalfollowingcdk46 pages 2-3)
A July 2024 public-database study evaluated CCND1 across 33 cancer types and reported significantly elevated expression in 13. Amplification was the predominant alteration, while expression–survival associations varied by tumor type: high expression correlated with poorer prognosis in head-and-neck squamous-cell and pancreatic adenocarcinomas but with more favorable outcomes in several other cancers. This heterogeneity argues against interpreting CCND1 expression as a universal adverse marker. Taha et al., published 27 July 2024, DOI 10.7759/cureus.65504. (taha2024ccnd1asa pages 26-26, taha2024ccnd1asa pages 1-2)
Across 46,206 patients in its cBioPortal survival analysis, the study included 2,385 CCND1-altered and 43,821 unaltered cases. Median overall survival was 39.66 versus 46.92 months, respectively (p=5.98×10⁻³; q=0.0239). By contrast, disease-specific, disease-free, and progression-free survival comparisons were nonsignificant. These findings are hypothesis-generating because they combine heterogeneous tumors and public datasets, lack prospective validation, and do not establish that CCND1 is independently prognostic or predictive. (taha2024ccnd1asa pages 22-26, taha2024ccnd1asa pages 2-3)
The highest-confidence annotation for human P24385 is: a mitogen-responsive, non-enzymatic cyclin that activates CDK4/6 in the nucleus to phosphorylate RB-family proteins and permit E2F-dependent G1/S progression. Its abundance and location are tightly controlled by transcription, complex assembly, nuclear trafficking, Thr286 phosphorylation, ubiquitination, and proteasomal degradation. This mechanism is supported by convergent biochemical, genetic, localization, and pharmacological evidence. (tchakarska2020thedoubledealing pages 26-30, saleban2023dtypecyclinsin pages 3-4, tchakarska2020thedoubledealing pages 5-9)
Noncanonical functions in transcription, DNA repair, metabolism, motility, and neuronal GABA-A-receptor regulation are credible but context dependent. Among them, the 2023 GABRA4 study provides unusually strong causal evidence because it combines direct interaction, identified phosphosites, electrophysiology, genetic loss, and rescue. Conversely, pan-cancer expression correlations and many proposed prognostic uses remain exploratory. (tchakarska2020thedoubledealing pages 13-17, pedraza2023cyclind1—cdk4regulates pages 10-13, pedraza2023cyclind1—cdk4regulates pages 1-2)
Clinically, the most mature implementations are cyclin D1/CCND1 testing in lymphoma diagnosis and pharmacological inhibition of CDK4/6 in breast cancer. Both require nuance: CCND1 rearrangement is not completely specific for MCL, and CCND1 abundance alone is not a validated universal predictor of CDK4/6-inhibitor response. The most defensible interpretation integrates CCND1 with cellular localization, RB competence, lineage, immunophenotype, rearrangement mechanism, and cooperating pathway lesions. (ozogul2024largebcelllymphomas pages 1-2, lopez2024biologicalandclinical pages 1-2, zhao2023anarrativereview pages 13-15)
References
(saleban2023dtypecyclinsin pages 3-4): Mostafa Saleban, Erica L. Harris, and James A. Poulter. D-type cyclins in development and disease. Genes, 14:1445, Jul 2023. URL: https://doi.org/10.3390/genes14071445, doi:10.3390/genes14071445. This article has 59 citations.
(saleban2023dtypecyclinsin pages 8-10): Mostafa Saleban, Erica L. Harris, and James A. Poulter. D-type cyclins in development and disease. Genes, 14:1445, Jul 2023. URL: https://doi.org/10.3390/genes14071445, doi:10.3390/genes14071445. This article has 59 citations.
(saleban2023dtypecyclinsin pages 1-3): Mostafa Saleban, Erica L. Harris, and James A. Poulter. D-type cyclins in development and disease. Genes, 14:1445, Jul 2023. URL: https://doi.org/10.3390/genes14071445, doi:10.3390/genes14071445. This article has 59 citations.
(tchakarska2020thedoubledealing pages 26-30): Guergana Tchakarska and Brigitte Sola. The double dealing of cyclin d1. Cell Cycle, 19:163-178, Dec 2020. URL: https://doi.org/10.48550/arxiv.2001.00837, doi:10.48550/arxiv.2001.00837. This article has 326 citations and is from a peer-reviewed journal.
(taha2024ccnd1asa pages 2-3): Muhammed Y Taha, Noha O Mohamed, Lina G Alhaj, Issra Altayeb, Abeer Basheer, Shaymaa Idrees, Abdirahman M Said, and Mohamed Alfaki. Ccnd1 as a prognostic and diagnostic biomarker and the impact of its epigenetic alterations on cancer survival. Jul 2024. URL: https://doi.org/10.7759/cureus.65504, doi:10.7759/cureus.65504. This article has 8 citations.
(tchakarska2020thedoubledealing pages 5-9): Guergana Tchakarska and Brigitte Sola. The double dealing of cyclin d1. Cell Cycle, 19:163-178, Dec 2020. URL: https://doi.org/10.48550/arxiv.2001.00837, doi:10.48550/arxiv.2001.00837. This article has 326 citations and is from a peer-reviewed journal.
(tchakarska2020thedoubledealing pages 17-21): Guergana Tchakarska and Brigitte Sola. The double dealing of cyclin d1. Cell Cycle, 19:163-178, Dec 2020. URL: https://doi.org/10.48550/arxiv.2001.00837, doi:10.48550/arxiv.2001.00837. This article has 326 citations and is from a peer-reviewed journal.
(tchakarska2020thedoubledealing pages 33-34): Guergana Tchakarska and Brigitte Sola. The double dealing of cyclin d1. Cell Cycle, 19:163-178, Dec 2020. URL: https://doi.org/10.48550/arxiv.2001.00837, doi:10.48550/arxiv.2001.00837. This article has 326 citations and is from a peer-reviewed journal.
(radel2023investigatingposttranslationalmodification pages 20-23): Shaelynn Radel. Investigating post-translational modification of cyclin d1 in breast cancer. ArXiv, 2023. URL: https://doi.org/10.5204/thesis.eprints.240785, doi:10.5204/thesis.eprints.240785. This article has 0 citations.
(tchakarska2020thedoubledealing pages 1-5): Guergana Tchakarska and Brigitte Sola. The double dealing of cyclin d1. Cell Cycle, 19:163-178, Dec 2020. URL: https://doi.org/10.48550/arxiv.2001.00837, doi:10.48550/arxiv.2001.00837. This article has 326 citations and is from a peer-reviewed journal.
(tchakarska2020thedoubledealing pages 13-17): Guergana Tchakarska and Brigitte Sola. The double dealing of cyclin d1. Cell Cycle, 19:163-178, Dec 2020. URL: https://doi.org/10.48550/arxiv.2001.00837, doi:10.48550/arxiv.2001.00837. This article has 326 citations and is from a peer-reviewed journal.
(saleban2023dtypecyclinsin pages 4-6): Mostafa Saleban, Erica L. Harris, and James A. Poulter. D-type cyclins in development and disease. Genes, 14:1445, Jul 2023. URL: https://doi.org/10.3390/genes14071445, doi:10.3390/genes14071445. This article has 59 citations.
(pedraza2023cyclind1—cdk4regulates pages 10-13): N. Pedraza, Ma Ventura Monserrat, F. Ferrezuelo, Jordi Torres-Rosell, Neus Colomina, F. Miguez-Cabello, Javier Picañol Párraga, D. Soto, Esperanza López-Merino, Celia García-Vilela, J. A. Esteban, J. Egea, and E. Garí. Cyclin d1—cdk4 regulates neuronal activity through phosphorylation of gabaa receptors. Cellular and Molecular Life Sciences, Aug 2022. URL: https://doi.org/10.1007/s00018-023-04920-7, doi:10.1007/s00018-023-04920-7. This article has 9 citations and is from a domain leading peer-reviewed journal.
(pedraza2023cyclind1—cdk4regulates pages 1-2): N. Pedraza, Ma Ventura Monserrat, F. Ferrezuelo, Jordi Torres-Rosell, Neus Colomina, F. Miguez-Cabello, Javier Picañol Párraga, D. Soto, Esperanza López-Merino, Celia García-Vilela, J. A. Esteban, J. Egea, and E. Garí. Cyclin d1—cdk4 regulates neuronal activity through phosphorylation of gabaa receptors. Cellular and Molecular Life Sciences, Aug 2022. URL: https://doi.org/10.1007/s00018-023-04920-7, doi:10.1007/s00018-023-04920-7. This article has 9 citations and is from a domain leading peer-reviewed journal.
(pedraza2023cyclind1·cdk4regulates pages 10-13): Neus Pedraza, Maria Ventura Monserrat, Francisco Ferrezuelo, Jordi Torres-Rosell, Neus Colomina, Federico Miguez-Cabello, Javier Picañol-Párraga, David Soto, Esperanza López-Merino, Celia García-Vilela, Jose Antonio Esteban, Joaquim Egea, and ELOI GARI. Cyclin d1·cdk4 regulates neuronal activity through phosphorylation of gabaa receptors. Cellular and Molecular Life Sciences, Jun 2023. URL: https://doi.org/10.21203/rs.3.rs-3058897/v1, doi:10.21203/rs.3.rs-3058897/v1. This article has 9 citations and is from a domain leading peer-reviewed journal.
(lopez2024biologicalandclinical pages 1-2): Cristina López, Elisabeth Silkenstedt, Martin Dreyling, and Sílvia Beà. Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma. Jul 2024. URL: https://doi.org/10.1182/bloodadvances.2023011763, doi:10.1182/bloodadvances.2023011763. This article has 26 citations and is from a peer-reviewed journal.
(ozogul2024largebcelllymphomas pages 1-2): Ece Özoğul, Anna Montaner, Melina Pol, Gerard Frigola, Olga Balagué, Charlotte Syrykh, Pablo Bousquets-Muñoz, Romina Royo, Juliette Fontaine, Alexandra Traverse-Glehen, Marco M. Bühler, Luca Giudici, Marco Roncador, Thorsten Zenz, Sylvain Carras, Severine Valmary-Degano, Laurence de Leval, Jan Bosch-Schips, Fina Climent, Julia Salmeron-Villalobos, Melika Bashiri, Silvia Ruiz-Gaspà, Dolors Costa, Sílvia Beà, Itziar Salaverria, Eva Giné, Leticia Quintanilla-Martinez, Pierre Brousset, Mark Raffeld, Elaine S. Jaffe, Xose S. Puente, Cristina López, Ferran Nadeu, and Elias Campo. Large b-cell lymphomas with ccnd1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma. Blood Cancer Journal, Sep 2024. URL: https://doi.org/10.1038/s41408-024-01146-z, doi:10.1038/s41408-024-01146-z. This article has 13 citations and is from a domain leading peer-reviewed journal.
(ozogul2024largebcelllymphomas pages 5-7): Ece Özoğul, Anna Montaner, Melina Pol, Gerard Frigola, Olga Balagué, Charlotte Syrykh, Pablo Bousquets-Muñoz, Romina Royo, Juliette Fontaine, Alexandra Traverse-Glehen, Marco M. Bühler, Luca Giudici, Marco Roncador, Thorsten Zenz, Sylvain Carras, Severine Valmary-Degano, Laurence de Leval, Jan Bosch-Schips, Fina Climent, Julia Salmeron-Villalobos, Melika Bashiri, Silvia Ruiz-Gaspà, Dolors Costa, Sílvia Beà, Itziar Salaverria, Eva Giné, Leticia Quintanilla-Martinez, Pierre Brousset, Mark Raffeld, Elaine S. Jaffe, Xose S. Puente, Cristina López, Ferran Nadeu, and Elias Campo. Large b-cell lymphomas with ccnd1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma. Blood Cancer Journal, Sep 2024. URL: https://doi.org/10.1038/s41408-024-01146-z, doi:10.1038/s41408-024-01146-z. This article has 13 citations and is from a domain leading peer-reviewed journal.
(taha2024ccnd1asa pages 22-26): Muhammed Y Taha, Noha O Mohamed, Lina G Alhaj, Issra Altayeb, Abeer Basheer, Shaymaa Idrees, Abdirahman M Said, and Mohamed Alfaki. Ccnd1 as a prognostic and diagnostic biomarker and the impact of its epigenetic alterations on cancer survival. Jul 2024. URL: https://doi.org/10.7759/cureus.65504, doi:10.7759/cureus.65504. This article has 8 citations.
(taha2024ccnd1asa pages 1-2): Muhammed Y Taha, Noha O Mohamed, Lina G Alhaj, Issra Altayeb, Abeer Basheer, Shaymaa Idrees, Abdirahman M Said, and Mohamed Alfaki. Ccnd1 as a prognostic and diagnostic biomarker and the impact of its epigenetic alterations on cancer survival. Jul 2024. URL: https://doi.org/10.7759/cureus.65504, doi:10.7759/cureus.65504. This article has 8 citations.
(zhao2023anarrativereview pages 13-15): Shidi Zhao, Haocheng Zhang, Na Yang, and Jin Yang. A narrative review about cdk4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer. Translational Cancer Research, 12:1617-1634, Jun 2023. URL: https://doi.org/10.21037/tcr-22-2807, doi:10.21037/tcr-22-2807. This article has 20 citations.
(zhao2023anarrativereview pages 1-2): Shidi Zhao, Haocheng Zhang, Na Yang, and Jin Yang. A narrative review about cdk4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer. Translational Cancer Research, 12:1617-1634, Jun 2023. URL: https://doi.org/10.21037/tcr-22-2807, doi:10.21037/tcr-22-2807. This article has 20 citations.
(pedraza2023cyclind1·cdk4regulates pages 1-2): Neus Pedraza, Maria Ventura Monserrat, Francisco Ferrezuelo, Jordi Torres-Rosell, Neus Colomina, Federico Miguez-Cabello, Javier Picañol-Párraga, David Soto, Esperanza López-Merino, Celia García-Vilela, Jose Antonio Esteban, Joaquim Egea, and ELOI GARI. Cyclin d1·cdk4 regulates neuronal activity through phosphorylation of gabaa receptors. Cellular and Molecular Life Sciences, Jun 2023. URL: https://doi.org/10.21203/rs.3.rs-3058897/v1, doi:10.21203/rs.3.rs-3058897/v1. This article has 9 citations and is from a domain leading peer-reviewed journal.
(pedraza2023cyclind1·cdk4regulates pages 13-16): Neus Pedraza, Maria Ventura Monserrat, Francisco Ferrezuelo, Jordi Torres-Rosell, Neus Colomina, Federico Miguez-Cabello, Javier Picañol-Párraga, David Soto, Esperanza López-Merino, Celia García-Vilela, Jose Antonio Esteban, Joaquim Egea, and ELOI GARI. Cyclin d1·cdk4 regulates neuronal activity through phosphorylation of gabaa receptors. Cellular and Molecular Life Sciences, Jun 2023. URL: https://doi.org/10.21203/rs.3.rs-3058897/v1, doi:10.21203/rs.3.rs-3058897/v1. This article has 9 citations and is from a domain leading peer-reviewed journal.
(OpenTargets Search: -CCND1): Open Targets Query (-CCND1, 11 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(giachetti2025survivalfollowingcdk46 pages 2-3): Pier Paolo Maria Berton Giachetti, Stefania Morganti, Sara Gandini, Fabiola Giudici, Antonio Marra, Eleonora Nicolò, Emma Zattarin, Chiara Corti, Laura Boldrini, Annarita Verrazzo, Caterina Sposetti, Maria Grazia Razeti, Ambra Carnevale Schianca, Roberta Scafetta, Beatrice Taurelli Salimbeni, Angela Esposito, Paola Zagami, Dario Trapani, Bianca Malagutti, Roberta Caputo, Claudio Vernieri, Elisabetta Munzone, Simone Scagnoli, Andrea Botticelli, Matteo Lambertini, Mario Giuliano, Michelino De Laurentiis, Giulia Viale, Giampaolo Bianchini, Giuseppe Curigliano, Carmine De Angelis, and Carmen Criscitiello. Survival following cdk4/6 inhibitor therapy for hormone receptor–positive, erbb2–negative metastatic breast cancer. JAMA Network Open, 8:e2461067, Feb 2025. URL: https://doi.org/10.1001/jamanetworkopen.2024.61067, doi:10.1001/jamanetworkopen.2024.61067. This article has 20 citations and is from a peer-reviewed journal.
(taha2024ccnd1asa pages 26-26): Muhammed Y Taha, Noha O Mohamed, Lina G Alhaj, Issra Altayeb, Abeer Basheer, Shaymaa Idrees, Abdirahman M Said, and Mohamed Alfaki. Ccnd1 as a prognostic and diagnostic biomarker and the impact of its epigenetic alterations on cancer survival. Jul 2024. URL: https://doi.org/10.7759/cureus.65504, doi:10.7759/cureus.65504. This article has 8 citations.